Quick Answer
Premarket Approval (PMA) is FDA's most stringent regulatory pathway, required for Class III medical devices that support or sustain human life or present a potential unreasonable risk. Unlike 510(k), PMA requires clinical evidence demonstrating safety and effectiveness. The FY2026 PMA application fee exceeds $400,000.
Regulatory Authority: 21 CFR Part 814 — Premarket Approval of Medical Devices; Section 515 of the FD&C Act
What Is Premarket Approval (PMA)?
Foreign Facility
Raw Data InputTranslation Layer
Validation ActiveFDA FURLS
Live SyncCompliance Vault
ImmutablePremarket Approval (PMA) is the FDA process for evaluating the safety and effectiveness of Class III medical devices. It is the most rigorous type of device marketing application, requiring clinical evidence that provides reasonable assurance that the device is safe and effective for its intended use.
PMA differs fundamentally from the 510(k) pathway. While 510(k) requires demonstrating "substantial equivalence" to a predicate device, PMA requires independent scientific evidence — typically from well-controlled clinical trials — proving the device works safely.
PMA vs. 510(k) at a Glance
| Feature | PMA | 510(k) |
|---|---|---|
| Device class | Class III (high risk) | Class II (moderate risk) |
| Standard | Safe and effective | Substantially equivalent |
| Clinical data | Usually required | Rarely required |
| Review time | 180 days (statutory) | 90 days (performance goal) |
| FY2026 fee | ~$421,000 (standard) | ~$26,000 (standard) |
When Is a PMA Required?
Foreign Supplier
HACCP Plan Required
Assurentry FSVP Engine
FDA Systems
Audit Ready Records
PMA is required for Class III medical devices unless the device qualifies for a different pathway. Class III devices include:
- Life-sustaining/supporting devices: Implantable pacemakers, heart valves, ventricular assist devices
- Implantable devices: Cochlear implants, artificial joints, breast implants
- Significant-risk devices: Products presenting potential unreasonable risk of illness or injury
Exceptions to PMA for Class III Devices
Some Class III devices may use alternative pathways:
- Pre-Amendments devices: Class III devices marketed before May 28, 1976, that FDA has not yet required PMA for, may remain on the market under 510(k)
- De Novo pathway: Novel lower-risk devices with no predicate can use De Novo classification instead of PMA
- Humanitarian Device Exemption (HDE): Devices for conditions affecting fewer than 8,000 individuals per year
PMA Application Components
A PMA application is a comprehensive document package. FDA provides detailed guidance on the required content:
Device Description
Complete description of the device including engineering drawings, photographs, components, materials, and principles of operation.
Non-Clinical Laboratory Studies
Bench testing, biocompatibility, electromagnetic compatibility, sterilization validation, and other laboratory data.
Clinical Investigations
Full reports of all clinical studies demonstrating safety and effectiveness, typically including IDE pivotal study results.
Manufacturing Information
Detailed manufacturing processes, quality controls, and compliance with QMSR (21 CFR Part 820) / ISO 13485:2016.
Proposed Labeling
All labeling including instructions for use, physician labeling, and patient labeling with risk/benefit information.
Software Documentation
For devices with software: level of concern assessment, software requirements, architecture, verification and validation.
Clinical data for PMA typically comes from an Investigational Device Exemption (IDE) study. For IDE guidance, see our IDE Guide.
The Advisory Panel Review Process
FDA Observation
"Procedures for verifying supplier controls were not adequately established."
CAPA Deployed
Assurentry auto-generates a 15-day response plan with acceptable corrective actions.
FDA may convene an advisory panel — a committee of independent clinical and scientific experts — to review PMA applications. Panel review is common for novel devices or those with significant public health implications.
Panel Meeting Process
Panel Scheduling
FDA schedules the panel meeting and publishes a Federal Register notice at least 15 days in advance.
Document Review
Panel members review FDA's summary of the PMA application and the applicant's executive summary.
Presentations
Both FDA reviewers and the applicant present their analyses of the clinical and non-clinical data.
Public Comment
Open public hearing session where interested parties can provide oral testimony.
Panel Vote
The panel votes on whether the data supports a finding of safety and effectiveness, with conditions if needed.
Important: The advisory panel's recommendation is not binding. FDA makes the final approval decision and may agree or disagree with the panel's vote.
PMA Supplements and Post-Approval Changes
Automated Extraction
Our systems parse complex FDA documents into actionable data instantly.
After PMA approval, any change that affects the safety or effectiveness of the device requires a PMA supplement. The type of supplement depends on the nature and significance of the change:
- 180-Day Supplement: For significant changes to design, manufacturing, or labeling that could affect safety/effectiveness
- Real-Time Supplement: For well-characterized changes that can be reviewed and approved in real-time (typically within 30 days)
- 30-Day Notice: For minor manufacturing changes that are unlikely to affect safety/effectiveness
- Annual Report: Minor changes that enhance device safety may be reported annually
- Panel-Track Supplement: For changes significant enough to potentially require advisory panel review
Post-Approval Studies
FDA may require post-approval studies as a condition of PMA approval. These studies monitor long-term safety and effectiveness in broader patient populations. Failure to conduct required post-approval studies can result in withdrawal of PMA approval.
PMA Timeline, Fees, and Success Strategies
The statutory review period for a PMA is 180 days from filing, but the actual timeline from first submission to approval averages 12-24 months due to FDA questions and additional information requests.
Pre-Submission Strategy
- Pre-Submission (Q-Sub) meetings: Request a pre-submission meeting with FDA to align on clinical study design, endpoints, and data requirements before submitting
- Breakthrough Device designation: Novel devices treating life-threatening conditions may qualify for priority review and interactive communication
- Modular PMA review: Submit and get feedback on individual modules (manufacturing, non-clinical) before the full PMA is complete
For 510(k) pathway details, see our 510(k) Guide. For device registration and listing, visit our Device Registration Guide.
Stop reading. Start executing.
Assurentry acts as a technical translation layer. You provide basic business info, and we automatically generate and file the exact electronic submissions required by the FDA.
Automate compliance100% FDA Acceptance Guaranteed